Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 17/20 | 0.49 |
| ▸ | JAK3 | P52333 | 16/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16009806 | 0.88 | JAK2 (0.49) | JAK2PTK2JAK3CDK2EGFR | |
| SCHEMBL17968675 | 0.82 | JAK2 (0.48) | JAK2PTK2JAK3CDK2CYP3A4 | |
| SCHEMBL16009357 | 0.77 | JAK2 (0.47) | JAK2PTK2JAK3CCNE1CDK2 | |
| SCHEMBL7467387 | 0.74 | CDK2 (0.64) | JAK2PTK2JAK3CCNE1CDK2 | |
| SCHEMBL2640495 | 0.70 | JAK2 (0.69) | JAK2PTK2JAK3JAK1ABCB1 | |
| SCHEMBL26176201 | 0.69 | CDK2 (0.56) | JAK2PTK2JAK3CCNE1CDK2 | |
| SCHEMBL30399350 | 0.69 | CDK2 (0.56) | JAK2PTK2JAK3CCNE1CDK2 | |
| SCHEMBL20272450 | 0.67 | L3MBTL1 (0.39) | — | |
| SCHEMBL2378486 | 0.67 | ADRA2C (0.61) | JAK2PTK2JAK3CDK2 | |
| SCHEMBL20242345 | 0.67 | JAK2 (0.53) | JAK2PTK2JAK3CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-9370515-B2 | Mixed lineage kinase inhibitors and method of treatments | Califia Bio, Inc. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20140256733-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | MAP3K2, MAP3K1, MAP3K20 | JAK2 320/4885PTK2 222/4885JAK3 367/4885 |
| US-20140256733-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | MAP3K2, MAP3K1, MAP3K20 | JAK2 320/4885PTK2 222/4885JAK3 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.